Customer
Description
Blue Horizon International (BHI) is a global leader in stem cell production, currently pursuing U.S. regulatory approval for its cell therapy.
Published in Q1 Journal; Frontiers in Medicine
1500 content downloads
"Co-Labb's research and thoroughness is the best in the industry and their commitment to meeting deadlines makes them indispensable to our company's success."
Elizabeth Mehling, Co-Founder - Blue Horizon International
Blue Horizon International (BHI) is a global leader in stem cell therapy, operating clinics worldwide. Their innovative treatments advance regenerative medicine, and they’ve built a reputation for delivering cutting-edge healthcare solutions. Academic publications were needed to back up BHI's expansion and to support regulatory and funding applications.
A Private Training for Biotech, Pharma & Healthcare Teams:
How To Transform Complex Science Into Content That Converts
The Challenge
BHI had extensive clinical data from their global operations but needed expert writers to develop this raw data into a polished manuscript for a peer-reviewed journal. They also needed support managing the entire publication process, ensuring the data could be leveraged for regulatory approvals, including their Investigational New Drug (IND) application with the FDA and future grant applications.
The Solution
Co-Labb provided BHI with a full publication management service:
Initial Consultation and Data Organisation: We worked with BHI to understand their objectives and organize their patient data, ensuring the most impactful information paper could be developed based on the available data.
Manuscript Drafting: We developed a comprehensive manuscript inline with the scope of the target journal.
Revisions and Quality Control: The manuscript underwent several rounds of quality checks to meet journal guidelines, incorporating BHI’s feedback along the way.
Journal Submission and Peer Review Management: We formatted and submitted the manuscript to Frontiers in Medicine and managed all communication and revisions throughout the peer review process.
A Private Training for Biotech, Pharma & Healthcare Teams:
How To Transform Complex Science Into Content That Converts
The Results
Co-Labb successfully published BHI’s clinical data in Frontiers in Medicine, a critical milestone supporting their IND application and future grant efforts.
Ranked as a Q1 journal by both JIF and CiteScore, Frontiers in Medicine is amongst the highest ranked journals in its category (medicine).
Frontiers is the 3rd most-cited and 6th largest research publisher, with Frontiers in Medicine being one of the publishers most highly cited and impactful journals, with 54.7 million total views and downloads in 2023. Due to the viewership, this journal was chosen for maximum reach amongst the medical community.
To date, the article has received 1570 total views and downloads, an excellent result for a case series in a niche topic.
This publication has been a cornerstone of their ongoing regulatory submissions and funding, by providing peer-reviewed evidence for the safety and efficacy of their novel immunotherapy.
Blue Horizon International has been extremely thrilled with the services provided by Co-Labb. Their extensive knowledge and exemplary scientific writing skills have assisted our organization in moving rapidly forward through dramatically increased peer-reviewed publications.
Elizabeth Mehling, Co-Founder - Blue Horizon International
Message from the Co-Labb Co-Founder
“It’s been a pleasure working with Blue Horizon International on their publication journey. Helping them bring their novel immunotherapy to the forefront through a peer-reviewed journal publication is a testament to what can be achieved with a collaborative approach. We look forward to continuing our partnership as they move forward with their regulatory and scientific goals.”
Dr. Dan Sheridan, Co-founder of Co-Labb
Industry:
Biotechnology
Company Size:
Startup
Working with Co-Labb since:
2021
Services Utilised:
Journal Manuscript Writing
Why BHI Chose Co-Labb
BHI selected Co-Labb for our comprehensive End-to-End Publication Management services. BHI was equally impressed by the quality of our medical writing team, consisting exclusively of PhD scientists who have many personal publications from their own personal research careers, demonstrating the first-hand expertise that we could offer. The deciding factor was our in-house capacity to offer the turnkey solution BHI required - handling every stage from manuscript drafting to journal submission, allowing BHI to focus on their clinical work.
.png)
ModernVivo Case Study
From Website Launch to Leadership: Building Authority with Science-Driven Content
Co-Labb partnered with ModernVivo to deliver a full website copy, white papers, blogs, and social media content, building trust, establishing authority, and enabling consistent, high-quality content creation.
Blue Horizon International Case Study
Co-Labb Supports Blue Horizon International’s FDA Pre-IND Submission with Regulatory Writing
Blue Horizon International partnered with Co-Labb for end-to-end support in their Pre-IND submission to the FDA.
Relevant Case Studies
Ready to transform your scientific content?
Elevate your brand, engage your audience, and drive growth with expertly crafted life science content. Whether you're looking to enhance thought leadership or generate high-quality leads, our tailored campaigns deliver results that matter.
Book a discovery call today and let's discuss how we can help you reach your goals.